type="text/javascript" charset="utf-8">
Step 1 Of 3
Policy Update: GLP-1 Weight Loss Medications – Effective August 1, 2025
Starting August 1, 2025, all prescriptions for GLP-1 medications used for weight loss (such as semaglutide and tirzepatide) will be written for brand-name products like Wegovy®, Ozempic®, or Zepbound®, in accordance with updated prescribing guidelines.
Compounded GLP-1 medications may still be available, but only if specific medical criteria are met—such as the need for non-standard dosing, documented intolerance, or lack of commercial availability.
Why the change?
These updates reflect evolving guidance from federal and state regulators to ensure safety, consistency, and legal compliance in GLP-1 therapy.
What this means for you:
If you're currently receiving a compounded version, we’ll review your treatment plan to ensure uninterrupted care and determine if continued use meets criteria.
As always, our priority is safe, evidence-based, personalized weight management. If you have questions, don't hesitate to reach out.